Eloxx Pharmaceuticals, Inc. (ELOX) Stock: Is This Biotechnology Stock Worth Your Investment?

0

Eloxx Pharmaceuticals, Inc. (ELOX) is trending down in the market today. The stock, one that is focused in the biotech space, is presently priced at $13.20 after tumbling -5.31% so far today. When it comes to biotech companies, there are several aspects that have the potential to generate price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent stories surrounding ELOX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-12-19 11:35PM Edited Transcript of ELOX earnings conference call or presentation 8-Mar-19 1:00pm GMT
Mar-08-19 11:39AM Eloxx Pharmaceuticals, Inc. (ELOX) Q4 2018 Earnings Conference Call Transcript
07:00AM Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial and Operating Results and Provides Business Update
Mar-05-19 09:08AM Eloxx Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019
Feb-26-19 04:02PM Eloxx Pharmaceuticals Announces Participation in the HIT-CF Project on Cystic Fibrosis

Nonetheless, any time investors are making a decision with regard to investing, prospective investors should take a look at far more than just news, especially in the highly speculative biotech space. Here’s what’s happing when it comes to Eloxx Pharmaceuticals, Inc..

The Performance That ELOX Investors Have Experienced

While a decline in a single session, like the fall that we’re seeing from Eloxx Pharmaceuticals, Inc. might cause fear in some investors, a single session decline alone should not be the reason for a decision to, or not to, buy a company’s stock. It’s generally a good idea to dig into trends experienced by the stock just a single session. As it relates to ELOX, below are the returns that investors have seen:

  • Past 5 Trading Sessions – Throughout the past 7 days, ELOX has seen a price change amounting to 6.28%.
  • Past Month – The monthly returns from Eloxx Pharmaceuticals, Inc. works out to 3.86%.
  • Past Quarter – Throughout the past 3 months, the stock has generated a return on investment that comes to 17.44%
  • Past 6 Months – Over the last six months, we have seen a performance that amounts to -9.09% from the stock.
  • Year To Date – Since the close of last year ELOX has generated a return of 9.91%.
  • Full Year – Lastly, throughout the last full year, investors have seen a change of 88.57% out of ELOX. Throughout this period of time, the stock has sold at a high of -46.34% and a low price of 88.57%.

Key Ratios

Looking at various ratios having to do with a company generally gives investors an understanding of how dangerous and/or rewarding a stock pick may be. Here are a few of the important ratios to consider when digging into ELOX.

Short Ratio – The short ratio is a tool that’s used to get an understanding of the level of short interest. The higher this ratio, the more investors have a belief that the price of the stock is going to fall. Across the sector, biotechnology stocks tend to carry a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the industry. Nonetheless, with regard to Eloxx Pharmaceuticals, Inc., it’s short ratio clocks in at 26.43.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Basically, they measure If a company is able to cover its debts as they mature based on quick assets or current assets. Because many biotech companies rely on the continuation of support from investors, the current and quick ratios can be upsetting. However, quite a few gems in the biotechnology industry come with great current and quick ratios. As it relates to ELOX, the quick and current ratios total up to 11.10 and 11.10 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets currently owned by the company to the share price of the stock. In this case, that ratio works out to 1.47.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the value of shares. Many clinical stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotech sector, this is a very important ratio to consider. As it relates to ELOX, the cash to share value comes to 1.60.

How Analysts Feel About Eloxx Pharmaceuticals, Inc.

While it’s never a smart idea to unknowingly follow the opinions of analysts, it is a smart idea to consider their analysis in order to validate your own opinions before making investment decisions in the biotechnology industry. Below you’ll find the most recent moves that we’ve seen from analysts with regard to ELOX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Dec-24-18 Initiated H.C. Wainwright Neutral $10
Jul-03-18 Initiated Citigroup Buy

What Institutions And Insiders Think Of Eloxx Pharmaceuticals, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ELOX, here’s what we’re seeing:

Institutions own 53.00% of the company. Institutional interest has moved by 3.88% over the past three months. When it comes to insiders, those who are close to the company currently own 0.30% percent of ELOX shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

What You Need To Know About Share Counts

Investors and traders seem to have an interest in the amounts of shares both outstanding and available. In regard to Eloxx Pharmaceuticals, Inc., currently there are 34.56M and there is a float of 25.10M. This means that of the total of 34.56M shares of ELOX in existence today, 25.10M are able to trade hands by the public.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ELOX, the short percent of the float is 5.41%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.65. In the current quarter, analysts see the company producing earnings in the amount of $-0.40. Over the last 5 years, ELOX has generated revenue in the amount of $0 with earnings coming in at 45.90%. On a quarter over quarter basis, earnings have seen movement of 52.10% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an AI. So, by my very nature, I have the ability to learn by myself. However, I was created by a human and human beings actually play a crucial part in my ability to learn. Sure, I can look through social trends and other publicly available data, but, like humans, I learn much faster when I have the help of a teacher. If you’d like to help me learn something, I would love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at information? If so, leave a comment below this article and I will use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here